Research Analysts Set Expectations for KROS FY2026 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Equities research analysts at Leerink Partnrs increased their FY2026 earnings per share estimates for shares of Keros Therapeutics in a report issued on Thursday, February 27th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($4.66) per share for the year, up from their previous estimate of ($4.86). The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share. Leerink Partnrs also issued estimates for Keros Therapeutics’ FY2027 earnings at ($4.16) EPS, FY2028 earnings at ($1.95) EPS and FY2029 earnings at ($2.60) EPS.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22. The firm had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%.

A number of other analysts have also issued reports on KROS. Wedbush lowered Keros Therapeutics from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $47.00 to $15.00 in a research note on Friday, January 17th. Oppenheimer decreased their price target on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a research report on Thursday, January 16th. HC Wainwright lowered their price target on shares of Keros Therapeutics from $47.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. Wells Fargo & Company reduced their price objective on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, February 27th. Finally, Jefferies Financial Group began coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating on the stock. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $42.33.

Keros Therapeutics Price Performance

NASDAQ:KROS opened at $11.10 on Monday. Keros Therapeutics has a 1 year low of $9.77 and a 1 year high of $72.37. The stock’s fifty day moving average price is $12.40 and its two-hundred day moving average price is $39.25. The company has a market cap of $449.63 million, a P/E ratio of -2.13 and a beta of 1.39.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors have recently made changes to their positions in the stock. KBC Group NV lifted its holdings in shares of Keros Therapeutics by 52.0% during the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after purchasing an additional 280 shares in the last quarter. AlphaQuest LLC lifted its stake in Keros Therapeutics by 469.0% during the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after purchasing an additional 2,964 shares during the last quarter. LMR Partners LLP purchased a new position in shares of Keros Therapeutics in the 3rd quarter worth about $213,000. Finally, Victory Capital Management Inc. purchased a new position in shares of Keros Therapeutics in the 3rd quarter worth about $216,000. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.